Kronos Bio Inc Phase 1/2 KB-0742 Data Update Call Transcript
Thank you, operator, and good afternoon, everyone. I'm Sarah Connors, Vice President of Investor Relations and Corporate Communications at Kronos Bio. Earlier today, we issued a press release on Kronos Bio's positive preliminary data from the Phase 1 dose escalation portion of the Phase 1/2 KB-0742 study at AACR Triple Meeting. You may find this press release on our website, kronosbio.com in the Investors section.
Today, you will hear from Kronos Bio management, including Dr. Norbert Bischofberger, President and Chief Executive Officer; and Dr. Jorge DiMartino, Chief Medical Officer and Executive Vice President of Clinical Development. Norbert and Jorge will provide a brief overview of Kronos Bio, our science, and the KB-0742 program.
KB-0742 is Kronos Bio's internally discovered, highly selective, oral cyclin dependent kinase 9 inhibitor being developed to treat MYC-dependent solid tumors. We are very pleased to have trial investigator. Dr. Miguel Villalona, Medical Oncologist and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |